EV/EBITDA Multiple: Amicus Pharma (FOLD)
Amicus Therapeutics (FOLD) advances biotechnology through partnerships with scientific centers. The historical EV/EBITDA ratio visualizes the results of such collaborations, and the value 111.85 captures this metric. Growth in orphan drug sales has provided the firm with financial autonomy. Leading positions in enzyme therapy for rare pathologies establish the company as a global player in a segment devoid of competition.
amicusrx.com (FOLD) - metric breakdowns and financial figures
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Amicus Therapeutics|FOLD - Long-Term Debt to Equity|Short-Term Debt to Equity Amicus Therapeutics, Inc.|FOLD - Company Cumulative Debt|Debt to Book Capitalization Ratio Amicus Corp|FOLD - Company Long-Term Debt|Company Short-Term Debts Amicus Therapeutics|Quick Liquidity amicusrx.com
- net income and valuation multiples indicators:
FOLD - Net Financial Result|Expected Profit Amicus Therapeutics|FOLD - Price to Earnings Ratio|Forward P/E Multiple Amicus Therapeutics|FOLD - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Amicus Corp|FOLD - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Amicus Therapeutics|FOLD - Net earnings per share for the last four quarters|Quarterly EPS earnings growth amicusrx.com|FOLD - Net earnings per share growth this year|Expected earnings per share growth for next year Amicus Therapeutics
Initial company analysis:FOLD (Amicus Pharma)
Amicus Therapeutics (FOLD) expansion into orphan drug markets requires significant capital expenditures, making the EV/EBITDA chart a key tool for monitoring financial stability. This metric compares the total enterprise value, including debt, against operating profit, allowing investors to promptly assess asset overvaluation and the risk of corporate degradation without waiting for quarterly reports.
Who Amicus Therapeutics competes with
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascendis Pharma Inc. ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA rhythmtx.com|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Crinetics Corp|EV/EBITDA Multiple NAMS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SLNO (soleno.life)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 89bio ETNB|Agios (AGIO) - Company Value to EBITDA|GPCR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RZLT: EV/EBITDA Multiple|LXRX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MBX Biosciences|Altimmune Inc (ALT) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aardvark Therapeutics Corp (AARD)|Enterprise Value to EBITDA Ratio Sagimet Biosciences Inc SGMT|EV/EBITDA Multiple BIOA (BioAge Labs, Inc.)|EV/EBITDA Multiple biomeafusion.com BMEA|QNCX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Fractyl Health Inc. (GUTS) - Enterprise Value to EBITDA Ratio|VTVT: EV/EBITDA Multiple|ATPC - Total Company Value to Operating Income Before Depreciation Ratio|PLUR (Pluristem Therapeutics) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Synlogic Corp (SYBX)|Enterprise Value to EBITDA Ratio LPCN (Lipocine)|EV/EBITDA Multiple matinasbiopharma.com (MTNB)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Spruce Biosciences SPRB|Total Company Value to Operating Income Before Depreciation Ratio Galecto Corporation (GLTO)|CTCX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation LUMO (lumos-pharma.com)|ONVO (Organovo) - Enterprise Value to EBITDA Ratio|RDUS: Enterprise Value to Operating Income Before Depreciation Ratio
